• Lumiracoxib (SKU B1458): COX-2 Selective Inhibition in Muscl

  2026-05-12

  This scenario-driven guide explores how Lumiracoxib (SKU B1458), a highly selective COX-2 inhibitor, addresses reproducibility and interpretive challenges in muscle injury and inflammation assays. With protocol-ready data and rigorous QC from APExBIO, Lumiracoxib enables precise cyclooxygenase-2 pathway modulation for reliable, publication-quality results.

• Placental Exosomal miR-519d-3p Drives Immune Imbalance in Pr

  2026-05-12

  This study reveals that miR-519d-3p, abundantly present in placenta-derived exosomes from preeclamptic patients, alters maternal immune cell function by promoting Jurkat T cell proliferation, inhibiting apoptosis, and skewing Th17/Treg balance. The findings provide mechanistic insight into immune tolerance disruption in preeclampsia and highlight potential assay strategies for investigating cell death and immune modulation.

• Annexin V: Translating Phosphatidylserine Biology to Precisi

  2026-05-11

  Explore how recombinant Annexin V bridges mechanistic insight and translational strategy in apoptosis detection. Drawing from foundational studies and workflow innovations, this article guides researchers through protocol optimization, cross-model applications, and the evolving landscape of precision cell death research. Highlighting APExBIO's validated reagent, we set a new standard for early apoptosis marker deployment in preclinical and clinical contexts.

• Mitocytosis Inhibition Enhances Mitochondrial Drug Delivery

  2026-05-11

  Deng et al. reveal that inhibiting mitocytosis—a migrasome-mediated expulsion of damaged mitochondria—can significantly improve the efficacy of mitochondria-targeted antimetastatic therapies in aggressive breast cancer models. Their dual-function nanoplatform, capable of both mitochondrial damage and mitocytosis inhibition, demonstrates a promising strategy for overcoming resistance in migrasome-rich tumors.

• H-89 and the Future of cAMP Signaling in Bone Metabolism

  2026-05-10

  Explore how H-89, a selective cAMP-dependent protein kinase inhibitor, unlocks new mechanistic insights into bone biology by bridging cAMP-PKA pathways and metabolic reprogramming. Drawing on the latest research in Wnt-mediated osteogenesis and O-GlcNAcylation, this article provides translational researchers with strategic guidance for leveraging H-89 in advanced signaling and metabolic studies, while addressing protocol best practices and emerging clinical implications.

• E-4031: The hERG Potassium Channel Blocker for Cardiac Resea

  2026-05-09

  E-4031 is a gold-standard hERG potassium channel blocker, enabling precise modeling of proarrhythmic substrates and QT interval prolongation in advanced cardiac electrophysiology research. This article unpacks practical applications, troubleshooting, and experimental protocols for leveraging E-4031’s unique properties in both classic and next-generation workflows.

• OSMI-1: Applied O-GlcNAc Transferase Inhibitor for Protein S

  2026-05-09

  OSMI-1 from APExBIO delivers precise, cell-permeable O-GlcNAc transferase inhibition for dissecting protein O-GlcNAcylation in live cell and model organism workflows. Its robust benchmark data and high purity make it a top choice for studies in ferroptosis, trophoblast biology, and mitochondrial homeostasis.

• LY2109761: Advanced TGF-β Receptor Type I and II Inhibition

  2026-05-08

  LY2109761 stands out as a rigorously validated TGF-β receptor type I and II dual inhibitor, driving breakthroughs in cancer metastasis, radiosensitization, and fibrosis research. This guide translates recent mechanistic insights into optimized experimental workflows, troubleshooting strategies, and application-specific protocol design.

• Sulfamonomethoxine Workflows: Veterinary, Aquaculture & Envi

  2026-05-07

  Sulfamonomethoxine (SMM) bridges veterinary, aquaculture, and environmental research with robust, evidence-backed workflows for infection control, biotransformation modeling, and toxicity benchmarking. APExBIO’s research-grade SMM enables precise protocol optimization, species-specific dosing, and advanced troubleshooting for translational scientists.

• LLC-PK1-MOCK/MDR1 Model Advances High-Throughput BBB Predict

  2026-05-07

  Hu et al. (2025) introduce an in vitro surrogate blood-brain barrier (BBB) model integrating LLC-PK1-MOCK/MDR1 cells and lysosomal trapping correction, enabling high-throughput and physiologically relevant prediction of CNS drug permeability. The study validates the model’s predictive accuracy and delineates key efflux and diffusion mechanisms, offering a robust platform for early-stage CNS drug screening.

• HyperPFU™ high-fidelity DNA polymerase: Practical PCR Guidan

  2026-05-06

  HyperPFU™ high-fidelity DNA polymerase is designed to address the technical challenges of PCR amplification for long, GC-rich, or otherwise difficult DNA templates, where standard Taq or lower-fidelity enzymes often fail. It is recommended for workflows requiring exceptional sequence fidelity and blunt-ended products but should not be used in protocols that require 3'-A overhangs or sticky ends.

• Spiroplasma eriocheiris Entry in Drosophila S2 Cells via End

  2026-05-06

  This study elucidates the mechanisms by which Spiroplasma eriocheiris invades Drosophila Schneider 2 (S2) cells, demonstrating a reliance on clathrin-mediated endocytosis and macropinocytosis. The findings advance understanding of invertebrate-pathogen interactions and provide a methodological framework for dissecting host cell entry, cytoskeletal involvement, and apoptotic responses.

• Applied Workflows for YM-155 Hydrochloride Survivin Inhibito

  2026-05-05

  YM-155 hydrochloride stands out as a potent, highly selective survivin inhibitor for apoptosis research, with proven efficacy across diverse cancer models. This article delivers advanced experimental workflows, protocol enhancements, and troubleshooting insights to maximize data quality and translational impact.

• CK2-Mediated Phosphorylation Modulates Plant Ceramide Syntha

  2026-05-05

  This study reveals that phosphorylation by casein kinase 2 (CK2) fine-tunes the activity and stability of LOH2, a key ceramide synthase in Arabidopsis, thereby modulating sphingolipid biosynthesis and immune responses. The findings clarify post-translational regulation of sphingolipid metabolism and provide new insights into plant defense signaling.

• Coumestrol Drives Ferroptosis to Suppress RA Synoviocyte Act

  2026-05-04

  This study reveals that coumestrol induces ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) by stabilizing mitochondrial PMAIP1 via TRIM3 pathway inhibition, resulting in reduced cell proliferation and inflammation. These insights suggest ferroptosis modulation as a promising therapeutic strategy for RA and provide mechanistic benchmarks for future ferroptosis assays.

445 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page